News Related to Alpelisib

Related coverage linked through entity extraction aliases.

Ferroptosis and Cuproptosis Emerge as Key Cancer Therapy Targets in New Studies

Jul 08, 2026

Studies highlight ferroptosis and cuproptosis in cancer therapy: a DDR1/VEGFR2 inhibitor reverses gastric cancer chemoresistance, GSH-responsive nanoparticles enhance HCC immunotherapy, and nutrient restriction boosts Sorafenib-induced ferroptosis.

Gedatolisib combinations beat alpelisib regimen in PIK3CA-mutant HR-positive breast cancer

May 05, 2026

Topline phase 3 VIKTORIA-1 results showed gedatolisib combinations improved progression-free survival versus alpelisib plus fulvestrant in PIK3CA-mutant HR-positive/HER2-negative advanced breast cancer. Celcuity plans a supplemental FDA filing based on the data.